Overview
As a committed life-long learner, I am awed by the continued advancements in the field of pediatric transplant and cellular therapy (PTCT). Following completion of my PTCT fellowship training at Duke, I have developed a career dedicated to expanding indications for PTCT and improving associated outcomes. I have a special interest in the mitigation of endotheliopathies and continue to lead global harmonization efforts related to management of toxicities of therapy. As the Division Chief of PTCT at Duke, I am committed to the ensuring our patients receive state of the art care with access to innovative research protocols that change the field. We are committed to training the next generation of physicians in our field with a commitment to global partnerships to improve care for patients across the world.
Current Appointments & Affiliations
Professor of Pediatrics
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Chief, Division of Pediatric Transplant & Cellular Therapy
·
2023 - Present
Pediatrics, Transplant and Cellular Therapy,
Pediatrics
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.
Journal Article Bone Marrow Transplant · February 2026 Full text Link to item CiteDefibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT).
Journal Article Bone Marrow Transplant · January 13, 2026 SOS/VOD is a life-threatening complication of hematopoietic stem cell transplantation, especially in children, with incidences reaching up to 15-20%. Despite efforts, SOS/VOD remains unpredictable with significant morbidity and mortality. High-risk criteri ... Full text Link to item CiteReduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507
Conference Blood · November 3, 2025 AbstractBackground: Allogeneic hematopoietic stem-cell transplantation has curative potential for sickle cell disease (SCD). Event-free sur ... Full text CiteRecent Grants
A Phase 1/2, Open-Label, Basket Study of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Clinical TrialPrincipal Investigator · Awarded by Adaptimmune LLC · 2024 - 2038A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR¿ss+/CD19+ depleted transplantation
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2029Phase 1/2 Open-Label, Single-Ascending-Dose Study of EN-374, a Helper-Dependent Adenoviral-Based Gene Therapy, in Participants with X-Linked Chronic Granulomatous Disease
Clinical TrialPrincipal Investigator · Awarded by Ensoma, Inc. · 2025 - 2027View All Grants
Education
St. George's University, School of Medicine (West Indies) ·
2003
M.D.
Adelphi University ·
1999
B.S.